Vancomycin is the antibiotic of choice for serious methicillin resistant Staphylococcus aureus (MRSA) infections. Low vancomycin concentrations increase the risk of therapeutic failure and drug resistance, whereas high concentrations increase the risk of drug toxicity. Low vancomycin concentrations have been associated with the emergence of Heteroogenous Vancomycin Intermediate S. Aureus (hVISA).
|Number of pages||1|
|Publication status||Published - 2012|
|Event||Antimicrobials 2012: Australian Society of Antimicrobials - Brisbane, Australia|
Duration: 23 Feb 2012 → 25 Feb 2012
Conference number: 13
|Period||23/02/12 → 25/02/12|